Name: Recombinant Anti-CD3 x Anti-GD2 Bispecific Antibody (sdAb-IgG)
SKU: BSSG-378
Rating: 5 (1 reviews)

Recombinant Anti-CD3 x Anti-GD2 Bispecific Antibody (sdAb-IgG) is formed by an IgG and two single domains antibodies (sdAbs). The sdAbs from an anti-GD2 antibody variable domain are respectively connected to the N terminus of the anti-CD3 IgG heavy chains or light chains to form sdAb-(H)IgG or sdAb-(L)IgG. It is a type of appended IgGs and has 2+2 antigen-binding valency. This BsAb can retarget T cells to tumor cells. It is designed for the research of Neuroblastoma; Osteosarcoma; Melanoma; Solid tumors therapy.

Datasheet INQUIRY

Specifications

Targets

CD3 & GD2

Type

sdAb-IgG

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Neuroblastoma; Osteosarcoma; Melanoma; Solid tumors

Host Animal 1

Mouse

Host Animal 2

llama

Targets

Target 1

CD3

Gene ID

916

UniProt ID

P07766

Alternative Names

CD3; CD3E; CD3e molecule; Cluster of differentiation 3; CD3e molecule, epsilon (CD3-TCR complex); T3E; TCRE; IMD18; T-cell surface glycoprotein CD3 epsilon chain; CD3-epsilon; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e antigen, epsilon polypeptide (TiT3 complex); T-cell antigen receptor complex, epsilon subunit of T3

Target 2

GD2

Alternative Names

Ganglioside GD2; GD2; Ganglioside; Disialoganglioside GD2

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CD3 x Anti-GD2 Bispecific Antibody (sdAb-IgG) (BSSG-378). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-CD3 x Anti-GD2 Bispecific Antibody (sdAb-IgG) (CAT#: BSSG-378)

Specifications

Targets

Customer Reviews and Q&As